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Background: The Real-time PCR Array System is the ideal tool for analyzing the expression of a focused panel of
genes. In this study, we will analyze the gene expression profile of pediatric acute myeloid leukemia with real-time
PCR arrays.
Methods: Real-time PCR array was designed and tested firstly. Then gene expression profile of 11 pediatric AML
and 10 normal controls was analyzed with real-time PCR arrays. We analyzed the expression data with MEV (Multi
Experiment View) cluster software. Datasets representing genes with altered expression profile derived from cluster
analyses were imported into the Ingenuity Pathway Analysis Tool.
Results: We designed and tested 88 real-time PCR primer pairs for a quantitative gene expression analysis of key
genes involved in pediatric AML. The gene expression profile of pediatric AML is significantly different from normal
control; there are 19 genes up-regulated and 25 genes down-regulated in pediatric AML. To investigate possible
biological interactions of differently regulated genes, datasets representing genes with altered expression profile
were imported into the Ingenuity Pathway Analysis Tool. The results revealed 12 significant networks. Of these
networks, Cellular Development, Cellular Growth and Proliferation, Tumor Morphology was the highest rated
network with 36 focus molecules and the significance score of 41. The IPA analysis also groups the differentially
expressed genes into biological mechanisms that are related to hematological disease, cell death, cell growth and
hematological system development. In the top canonical pathways, p53 and Huntington’s disease signaling came
out to be the top two most significant pathways with a p value of 1.5E-8 and2.95E-7, respectively.
Conclusions: The present study demonstrates the gene expression profile of pediatric AML is significantly different
from normal control; there are 19 genes up-regulated and 25 genes down-regulated in pediatric AML. We found
some genes dyes-regulated in pediatric AML for the first time as FASLG, HDAC4, HDAC7 and some HOX family
genes. IPA analysis showed the top important pathways for pediatric AML are p53 and Huntington’s disease
signaling. This work may provide new clues of molecular mechanism in pediatric AML.
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Pediatric acute myeloid leukemia (AML) comprises up to
20% of all childhood leukemia. Pediatric AML is a hetero-
geneous clonal disorder of hematopoietic progenitor cells,
which lose the ability to differentiate normally and to re-
spond to normal regulators of proliferation [1,2]. Gene
microarray technology provides a powerful tool for* Correspondence: panjian2008@163.com
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reproduction in any medium, provided the orcharacterizing gene expression on a genome scale [3-6].
Both cDNA and oligonucleotide-spotted microarrays have
been used to find genes discriminative for the different
genetic subgroups of pediatric AML [7]. Most reprodu-
cible and extensive results have been obtained using Affy-
metrix Gene Chips since these microarrays contain
multiple perfect matches and mismatch oligonucleotides
per gene and have been thoroughly validated. These stud-
ies in pediatric AML revealed new insights into the under-
lying biology of the different leukemic subtypes whichral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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specifically [8-10].
While microarray has been widely used in discovery-
based medical and basic biological research, its direct
application in clinical practice and regulatory decision-
making has been questioned [11-13]. A few key issues,
including the reproducibility, reliability, compatibility
and standardization of microarray analysis and results,
must be critically addressed before any routine usage of
microarrays in clinical laboratory and regulated areas.
However, in the absence of a "gold standard" or common
reference for gene expression measurements, these eva-
luations and comparisons have often yield subjective and
conflicting conclusions [14-18].
Real-time PCR is widely considered the gold standard
for gene expression measurement due to its high assay
specificity, high detection sensitivity and wide linear dy-
namic range. In addition to the TaqMan assay, the SYBRW
Green PCR assay is another commonly used real-time
PCR technique which is employed by half of all real-time
PCR users. SYBR Green PCR is widely used because of
the ease in designing the assays and its relatively low setup
and running costs [19,20]. One drawback of SYBR Green
assays, however, is that the dye is non-specific and can
generate false positive signals if non-specific products or
primer-dimmers are present in the assay [21]. Those pro-
blems can be addressed by carefully designing the primers
and validating the PCR products with dissociation curve
analysis immediately after PCR.
So the Real-time PCR Array System is the ideal tool
for analyzing the expression of a focused panel of genes.
The flexibility, simplicity, and convenience of standard
SYBR Green PCR detection methodology make the PCR
Array System accessible for routine use in any research
laboratory [22]. The specificity of the system guarantees
the amplification of only one gene-specific product in
each reaction meaning that the expression level result
confidently reflects only the gene of interest. The
present study demonstrates SYBR Green Real-time PCR
Arrays to be a quantitative platform with high inter run
and inter-laboratory reproducibility. PCR Arrays pro-
duce gene profiling differences between the two RNA
samples that are highly concordant with those generated
by other quantitative gene expression analysis and
microarray platforms. PCR Arrays deliver results com-
parable to those of high-density microarrays. Moreover,
it yields results similar to those of TaqMan Gene Expres-
sion Assays, a widely accepted method for validating
microarray results, and other more complicated and
more expensive quantitative methods tested by the Taq-
Man assay [19].
In this study, we will analyze the dyes-regulation genes
and pathways in pediatric AML with this powerful plat-
form, Real-time PCR arrays.Results and discussion
Design the Real-time PCR array
We designed and tested 88 real-time PCR primer pairs
for a quantitative gene expression analysis of key genes
involved in pediatric AML (Additional file 1). Briefly ,we
assayed the expression of 11 genes of HOX family
[HOXA1, HOXA3, HOXA4, HOXA5, HOXA7, HOXA9,
HOXB6, HOXB7, HOXB9 and HOXB9], 15 apoptosis
related genes [CASP1, CASP4, CASP8, BCL2, BIK,
BIRC5, BAX, BCL2L1, S100A8, S100A9, ID1, ID2,ID3,
ID4 and TNF], 7 chemokines [CCL5, CCR1, CCR2,
CCR4, CCR5 and CXCR4 ], 13 tumor related genes
[WT1, BRCA1 ,NF1, RB, APC, TP53BP1, PTEN, TP53 ,
CDKN1A, CDKN2B, CDKN1C, Jun and CCNB1] and 17
important genes in leukemia[ HMBS, CDH1, STAT4,
TIMP1,CD44, CDC42, DDX1, DKK3, HMGB2, STMN1,
STMN2, MEIS1, MEIS2, IGFBP3, IL6, LGALS4 and
GSK3B]. Each gene was tested the expression analysis
and melting curve analysis to make sure the primer is
specific for the target gene. The average CV for the CT
values generated from assays on the PCR Array is found
to be 0.73% with replicate measurements for CT values
below 30 within 0.20 cycle average standard deviation,
demonstrating a good inter-run reproducibility.
Expression profile analysis of pediatric AML and normal
control samples
We analyzed gene expression profile of pediatric AML
and control samples with our Real-time PCR arrays
(Figure 1A). The information of 10 normal control and
11 pediatric AML samples are listed in Table 1. After we
get the original data, we analyzed the expression data
with MEV (Multi Experiment View) cluster software.
The gene expression profile of pediatric AML is signifi-
cantly different from normal control, set of genes can be
successfully clustered (Figure 1B). The results showed
compared with normal control, there are 19 genes up-
regulated and 25 genes down-regulated in pediatric
AML (Table 2 and 3). The detailed expression of each
up-regulated gene in pediatric AML was presented in
Figure 2 and the expression of down-regulated genes
was presented in Figure 3. Some of the dyes-regulated
genes are consistent with other’s report, such as BIRC5,
WT1, BCL2, S100A8 and CDKN2B. Oto et al. showed
high expression of survivin in AML and survivn is a bad
prognostic indicator in cases with acute leukemia espe-
cially in AML [23]. Barragan et al. showed that the
Wilms' tumor (WT1) gene is over expressed in patients
with most forms of acute leukemia. WT1 expression was
significantly higher in AML patients than in normal con-
trols (p =0.0001) [24]. Twenty-five patients with ALL
and 65 patients with AML, both recently diagnosed,
were included into a study. A high frequency of BCL2
mRNA over expression and a relatively low frequency of
Figure 1 Expression profile analysis of pediatric AML and normal control samples. (A) Amplification data of Real-time PCR arrays in the
NBM and pediatric AML. (B) Cluster analysis the data from Real-time PCR arrays.
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Table 1 Pediatric acute myeloid leukemia patients’ clinical feature
Age Sex Hb WBC RBC PLt Diagnosis Chromosome Fusion gene
1 7 M 80 455. 8 2. 88 15 AML- M1 46,XY HOX11
2 4 F 83 136. 1 3. 09 11 AML- M1 46,XY ns
3 5 F 73 38. 83 2. 25 14 AML- M5b 46,XY,t ( 1, 11) ( q21; q23) ns
4 9 M 45 2. 47 1. 49 10 AML- M3 46, XY,t ( 11; 21) , t ( 15; 17) [ 12] / 46, XY, [ 3] PML/ RARA
5 0.9 F 76 56. 95 3. 52 155 AML- M4b ns MLL/ AF19
6 3 M 82 19. 58 2. 68 11 AML- M7 46,XY,t ( 2; 16)(q37; q12) , t ( 12, 20) ( p13, q11) ns
7 0.9 F 73 323. 54 2. 74 33 AML- M4b ns ns
8 4 M 80 7. 97 2. 3 91 AML- M5 ns AML/ ETO
9 11 M 80 35. 3 2. 45 75 AML- M3a 46, XY PML/ RAR1
10 6 M 68 39. 4 2. 39 18 AML- M3 46,XY PML/ RARA
11 7 F 54 4. 56 1. 75 17 AML- M3 46,XX,t ( 15; 17) ( q22; q21) [ 3] / 46,XX[ 12] PML/ RARA
Hb: Hemoglobin WBC: White blood cells RBC: Red blood cells PLt: Platelet.
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leukemia in this study, indicate that altered transcription
of these genes may be involved in leukemogenesis [25].
Nicolas et al. used mass spectrometry (MS)-based prote-
omic approaches to characterize that S100A8 is up-
regulated in leukemia cells and the expression of
S100A8 in leukemic cells is a predictor of low survival
[26]. CDKN2B appears to be frequently deleted and
methylated in AML [27-30].
This work also indicates some genes dyes-regulated in
pediatric AML for the first time. FASLG, the protein
encoded by this gene is the ligand for FAS. InteractionTable 2 Genes up regulated in the pediatric acute myeloid le
Gene Description
1 BI RC5 Baculoviral IAP repeat containing 5,survivin
2 FASLG Fas ligand (TNF superfamily, member 6)
3 WT1 Wilms tumor 1
4 AREG Amphiregulin
5 BCL2L1 BCL2-like 1
6 HDAC4 Histone deacetylase 4
7 CXCR4 Chemokine (C-X-C motif) receptor 4
8 HDAC7 Histone deacetylase 7
9 S100A9 S100 calcium binding protein A9
10 CD44 CD44 molecule (Indian blood group)
11 S100A8 S100 calcium binding protein A8
12 STMN2 Stathmin-like 2
13 NF1 Neurofibromin 1
14 CASP4 Caspase 4
15 BCL- 2 B-cell CLL/lymphoma 2
16 BI K BCL2-interacting killer (apoptosis-inducing)
17 PTEN Phosphatase and tensin homolog
18 CASP1 Caspase 1
19 CCL 5 Chemokine (C-C motif) ligand 5
NBM: Mean value of the gene expression in NBM group AML: Mean value of the geof FAS with this ligand is critical in triggering apoptosis
of some types of cells such as lymphocytes. The Fas/FasL
system as an important pathway inducing cell apoptosis
participates in occurrence and development of leukemia.
Leukemia cells generally are not sensitive or are resistant
to Fas/FasL-mediated apoptosis, while it is one of im-
portant reasons resulting in immunoescape and unsensi-
tivity of leukemia cells to chemotherapy. In recent years
studies related to mechanisms of leukemia cell resistance
to Fas/FasL-mediated apoptosis such as Fas and FasL
mutation and expression abnormality, Fas signaling
transduction pathway abnormality, and regulatory affectukemia compared with normal control
NBM AML Fold change P
34. 0496 221. 4575 6. 504 <0. 0001
0. 0005 0. 0308 57. 068 <0. 0001
3. 7431 14. 5000 3. 874 <0. 0001
0. 9960 4. 6307 4. 649 <0. 0001
7. 6435 27. 1093 3. 547 0. 0002
0. 0924 1. 0273 11. 117 0. 0002
24. 1547 1029. 2052 42. 609 0. 0004
0. 7191 11. 6169 16. 155 0. 0006
0. 4583 185. 0090 403. 722 0. 0007
2. 1648 312. 4866 144. 349 0. 0007
0. 0027 79. 0206 29736. 015 0. 0007
0. 1887 1. 2260 6. 497 0. 0007
0. 0553 0. 3749 6. 775 0. 0009
0. 1491 218. 1356 1463. 137 0. 0009
6. 1230 60. 3025 9. 849 0. 0009
3. 3040 26. 2063 7. 932 0. 001
0. 5800 1. 4595 2. 516 0. 001
0. 3028 79. 9140 263. 884 0. 004
0. 0288 872. 0606 30237. 515 0. 004
ne expression in pediatric AML group.
Table 3 Genes down regulated in the pediatric AML compared with normal control
Gene Description NBM AML Fold Change P
1 HOXB9 Homeobox B9 172. 9526 0. 6802 0. 004 <0. 0001
2 HOXA5 Homeobox A5 925. 5920 3. 4967 0. 004 <0. 0001
3 I D3 I nhi bi t or of DNA bi ndi ng 3 531. 6130 3. 0212 0. 006 <0. 0001
4 I GF2 Insulin-like growth factor 2 3. 4683 0. 0056 0. 002 <0. 0001
5 I D4 I nhi bi t or of DNA bi ndi ng 4 1422. 5193 0. 1906 0. 000 <0. 0001
6 FOXC1 Forkhead box C1 3676. 7938 26. 5854 0. 007 <0. 0001
7 HOXA7 Homeobox A7 15. 3933 0. 2396 0. 016 <0. 0001
8 CXCL1 Chemokine (C-X-C motif) ligand 1 0. 1130 0. 0022 0. 020 <0. 0001
9 HOXC9 Homeobox C9 138. 5471 4. 6762 0. 034 <0. 0001
10 HOXA3 Homeobox A3 16. 0470 0. 5843 0. 036 <0. 0001
11 HOXA4 Homeobox A4 263. 9704 7. 3403 0. 028 <0. 0001
12 DKK3 Dickkopf 3 homolog 8. 4810 0. 3344 0. 039 <0. 0001
13 JUN Jun pr ot o- oncogene 1005. 8731 35. 1804 0. 035 <0. 0001
14 STAT4 Signal transducer and activator of transcription 4 11. 5854 0. 5332 0. 046 <0. 0001
15 HOXB1 Homeobox B1 23. 4942 0. 8037 0. 034 <0. 0001
16 FGFR1 Fibroblast growth factor receptor 1 3. 7172 0. 2184 0. 059 <0. 0001
17 FOXM1 For khead box M1 789. 1920 177. 9791 0. 226 0. 0008
18 HDAC2 Histone deacetylase 2 2925. 0236 618. 9588 0. 212 0. 0008
19 HMBS Hydr oxymet hyl bi l ane synt hase 233. 0075 46. 3417 0. 199 0. 0008
20 I D1 I nhi bi t or of DNA bi ndi ng 1 140. 4811 14. 8120 0. 105 0. 0008
21 I D2 I nhi bi t or of DNA bi ndi ng 2 1221. 3259 360. 7765 0. 295 0. 001
22 CDKN2B Cyclin-dependent kinase inhibitor 2B 23. 9879 5. 1419 0. 214 0. 001
23 DDX1 DEAD ( Asp- Gl u- Al a- Asp) box hel i case 1 2039. 8291 681. 2089 0. 334 0. 001
24 HDAC1 Histone deacetylase 1 1196. 1914 449. 9266 0. 376 0. 002
25 BRCA1 Br east cancer 1, ear l y onset 12. 8548 4. 4127 0. 343 0. 004
NBM: Mean value of the gene expression in NBM group AML: Mean value of the gene expression in pediatric AML group.
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as strategies replying to antiapoptosis of leukemia cells
including NF-kappa B, XIAP, membrane receptor CD28
and matrix metalloproteinase 7 obtained some pro-
gresses [31]. HDACs, this work showed HDAC4 and
HDAC7 up-regulated, HDAC1 and HDAC2 down-
regulated in pediatric AML. Recruitment of HDAC4 is
necessary for PLZF-mediated repression in both normal
and leukaemic cells [32]. Ectopic expression of PML
recruits HDAC7 to PML NBs and leads to activation of
MEF2 reporter activity [33]. HDACs 1 is critical in en-
hancing cytarabine-induced apoptosis in pediatric AML,
at least partly mediated by Bim [34]. Evaluated the
mRNA gene expression profile of 12 HDAC genes by
quantitative real-time polymerase chain reaction in 94
consecutive childhood acute lymphoblastic leukaemia
(ALL) samples and its association with clinical/biological
features and survival. ALL samples showed higher ex-
pression levels of HDAC2, HDAC3, HDAC8, HDAC6
and HDAC7 when compared to normal bone marrow
samples. HDAC1 and HDAC4 showed high expression
in T-ALL and HDAC5 was highly expressed in B-lineageALL [35]. And these results may indicate a different ex-
pression profile of histone deacetylases (HDACs) be-
tween pediatric ALL and AML. Histones play a critical
role in transcriptional regulation, cell cycle progression,
and developmental events. HDACs is common feature
in several human malignancies and may represent an
interesting target for cancer treatment, including
hematological malignancies. This work also found 7
HOX genes down-regulated in pediatric AML. HOX
gene transcription during definitive hematopoiesis is
tightly regulated, but in a temporal manner [36]. In
AML, increased expression of HoxB3, B4, A7–11 is
found in the most primitive progenitors with expression
of A7–11 aberrantly sustained in differentiating progeni-
tors [37,38]. This study indicate an novel profile of HOX
genes down-regulated in pediatric AML and these obser-
vations suggest that analyzing the expression profile of
HOX genes would provide useful insights into pediatric
myeloid leukemogenesis. Expression of HOX B6 and
HOX B9 in NB4 and HL-60cells increase at a mid stage
of myeloid differentiation by ATRA induction and then
decrease during a late stage [39]. The phenotypic survey
Figure 2 Expression of up-regulated genes in pediatric AML. The expression of the pediatric AML samples compared to the control samples
was presented average± SE. A p <0.05 was considered statistically significant.
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this gene in regulating morphogenesis and specifying re-
gional identity along the embryo. A majority of Hoxa5
mutant pups die at birth from defective respiratory tract.
Surviving mutants present deficient alveolar septation
revealing the importance of Hoxa5 during formation
and maturation of the lung. The implication of Hoxa5 intumorigenesis has also been documented, the loss of
Hoxa5 function limits leukaemia associated with specific
chromosomal translocations. Thus, inappropriate Hoxa5
gene expression may disrupt normal growth and differ-
entiation programs causing neoplasia [40]. Hypermethy-
lation of HOXA5 is a good prognostic factor of AML
patients. The patients of the AML group who had high
Figure 3 Expression of down-regulated genes in pediatric AML. The expression of the pediatric AML samples compared to the control
samples was presented average ± SE. A p <0.05 was considered statistically significant.
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overall survival. Cox proportional hazards regression
showed that the methylation percentages of HOXA5 wereindependently associated with the 3-year overall survival
of AML patients [36]. HOXA4 gene expression is a pre-
dictor for outcome in normal karyotypic AML patients.
Yan-Fang et al. Cancer Cell International 2012, 12:40 Page 8 of 12
http://www.cancerci.com/content/12/1/4077% AML patients with HOXA4 hypermethylated and the
low HOXA4 expression is a favourable predictor for out-
come in AML patients [41].
Ingenuity pathway analysis the dyes-regulated genes in
pediatric AML
To investigate possible biological interactions of differ-
ently regulated genes, datasets representing genes with
altered expression profile derived from real-time PCR
array analyses were imported into the Ingenuity Pathway
Analysis Tool. The list of differentially expressed genes
analyzed by IPA revealed 12 significant networks.
Figure 4A represents the list of top 4 networks identified
by IPA. Of these networks, Cellular Development, Cellu-
lar Growth and Proliferation, Tumor Morphology was
the highest rated network with 36 focus molecules and
the significance score of 41 (Figure 4D). The score is the
probability that a collection of genes equal to or greater
than the number in a network could be achieved by
chance alone. A score of 3 indicates a 1/1000 chance
that the focus genes are in a network not due to random
chance.
The IPA analysis also groups the differentially expressed
genes into biological mechanisms that are related to can-
cer groups, hematological disease, cell death, cell growth
and proliferation, cardiovascular system development and
function, tumor morphology and hematological system
development and function (Figure 4B). In the toxicology
list, p53 and Huntington’s disease signaling came out to
be the top two most significant pathways with a p value of
1.5E-8 and2.95E-7, respectively (Figure 4C). The genes
associated with the top toxicology list are also given in the
Additional file 2.
This IPA analysis showed in pediatric AML the top
important pathways are p53 and Huntington’s disease
signaling. P53 protein expression has been widely inves-
tigated in leukemia and there are hundreds of papers
about the important roles of p53 in the pediatric
leukemia [42-50]. But there is still no report about the
relationship between Huntington’s disease signaling and
AML. This work may provide new clues of molecular
mechanism in pediatric AML.
Conclusions
The present study demonstrates the gene expression
profile of pediatric AML is significantly different from
normal control; there are 19 genes up-regulated and 25
genes down-regulated in pediatric AML. We found some
genes dyes-regulated in pediatric AML for the first time
as FASLG, HDAC4, HDAC7 and some HOX family
gene. IPA analysis showed the top important pathways
for pediatric AML are p53 and Huntington’s disease sig-
naling. This work may provide new clues of molecular
mechanism in pediatric AML.Methods
Patients and samples
Bone marrow specimens were obtained at the time of
diagnosis during routine clinical assessment of 11 patients
with AML, who presented at the Department of
Hematology and Oncology, Children's Hospital of Soo-
chow University between 2011 and 2012. Ethical approval
was provided by the Children's Hospital of Soochow Uni-
versity Ethics Committee (No. SUEC2010-011), and
informed consent was obtained from the parents or guar-
dians. AML diagnosis was made in accordance with the
revised French–American–British (FAB) classification.
The main clinical and laboratory features of the patients
cohort are summarized in Table 1. Additionally, bone
marrow samples from 10 healthy donors were analyzed as
controls. Bone marrow mononuclear cells (BMNCs) were
isolated using Ficoll solution within 2 h after bone marrow
samples harvested and immediately subjected for the ex-
traction of total RNA.
RNA extraction
For RNA extraction, bone marrow samples were imme-
diately submerged in 2 ml Trizol (Invitrogen), stored at
−80°C until further processed. A volume of 1 ml of each
sample was spun at 4°C for 15 min at 12,000 g to re-
move debris and DNA, 1 ml of supernatant was mixed
with 200 ul chloroform, shaken for 15 seconds, incu-
bated at RT for 2–3 minutes and spun for 10 min at
12,000 g at 4°C. RNA was precipitated by adding 500 ul
of the aqueous phase to an equal volume of isopropanol
and spun at 14,000 g at 4°C for 10 min. RNA was
washed with 75% ethanol, spun at 14,000 g at 4°C for
10 min, dried and resuspended in 40 ul DEPC-treated
H2O. The final RNA concentration was determined
using a spectrophotometer (Nanodrop 2000) and the
purity was assessed by agarose gel electrophoresis.
CDNA synthesis
CDNA synthesis was performed on 4 ug of RNA in a 10
ul sample volume using SuperScript II reverse transcript-
ase (Invitrogen) as recommended by the manufacturer.
The RNA was incubated with 0.5 ug of oligo (dT) 12–
18mers primers (Invitrogen) for 7 min at 70°C and then
transferred onto ice. Then, 9 ul of a master mix contain-
ing 4 ul of SuperScript II buffer, 2 ul of 0.1 M DTT (Invi-
trogen), and 1 ul each of dNTPs stock (10 mM)
(Invitrogen), Rnasin (40 UI) (Promega) and SuperScript
II (Invitrogen) were added to the RNA sample, spun and
incubated at 42°C for 60 min followed by 5 min at 70°C
to inactivate the enzyme. CDNA was stored at −20°C.
Real-time PCR array design and test
Most of the primers were from a database of Real-time
primers, Center for Medical Genetics (http://medgen.
Figure 4 (See legend on next page.)
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Figure 4 Ingenuity Pathways Analysis (IPA) summary. (A) The list of top four networks with their respective scores obtained from IPA. (B) The
list of top five bio functions with their respective scores obtained from IPA. (C) Toxicology pathway list in IPA analysis. The x-axis represents the
top toxicology functions as calculated by IPA based on differentially expressed genes are highlighted and the y-axis represents the ratio of
number of genes from the dataset that map to the pathway and the number of all known genes ascribed to the pathway. The yellow line
represents the threshold of p value, 0.05 as calculated by Fischer’s test. (D) Most highly rated network in IPA analysis. The network representation
of the most highly rated network. The genes that are shaded were determined to be significant from the statistical analysis. A solid line
represents a direct interaction between the two gene products and a dotted line means there is an indirect interaction.
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using the online program Primer 3 (www.fokker.wi.mit.
edu/primer3/input.htm). Primer selection parameters
were set to primer size: 20–26 nts; primer melting
temperature: 60 to 64°C; GC clamp: 1; and product size
range: generally 120–240 bp but down to 100 bp if no
appropriate primers could be identified. Primers were
ordered from Invitrogen. (Genes and sequence of the
primers was presented in Additional file 1).
Real-time PCR array analysis
Real-time PCR array analysis was performed in a total
volume of 20 ul including 2ul of cDNA, primers
(0.2 mM each) and 10 ul of SYBR Green mix (Roche).
Reactions were run on an Light cycler 480 (Roche) using
the universal thermal cycling parameters (95°C 5min,
45 cycles of 10 sec at 95°C, 20 sec at 60°C and 15 sec at
72°C; melting curve: 10 sec at 95°C, 60 sec at 60°C and
continues melting). Results were obtained using the se-
quence detection software Light cycler 480 and analyzed
using Microsoft Excel. For all samples melting curves
were acquired for quality control purposes. For gene ex-
pression quantification, we used the comparative Ct
method. First, gene expression levels for each sample
were normalized to the expression level of the house-
keeping gene encoding Glyceraldehydes 3-phosphate de-
hydrogenase (GAPDH) within a given sample (−⊿Ct);
the relative expression of each gene was calculated with
106 *Log2(−⊿Ct ).The difference between the pediatric
AML samples compared to the control samples was used
to determine the106 *Log2(−⊿Ct ). Statistical significance
of the gene expression difference between the AML and
the control samples was calculated with the T-test using
SPSS 11.5 software.
Ingenuity pathway analysis (IPA)
Datasets representing genes with altered expression
profile derived from Real-time PCR array analyses
were imported into the Ingenuity Pathway Analysis
Tool (IPA Tool; Ingenuity H Systems, Redwood City,
CA, USA; http://www.ingenuity.com). In IPA, differen-
tially expressed genes are mapped to genetic networks
available in the Ingenuity database and then ranked by
score. The basis of the IPA program consists of the In-
genuity Pathway Knowledge Base (IPKB) which is derivedfrom known functions and interactions of genes pub-
lished in the literature. Thus, the IPA Tool allows the
identification of biological networks, global functions and
functional pathways of a particular dataset. The program
also gives the significance value of the genes, the other
genes with which it interacts, and how the products of
the genes directly or indirectly act on each other, includ-
ing those not involved in the microarray analysis. The
networks created are ranked depending on the number of
significantly expressed genes they contain and also list
diseases that were most significant. A network is a graph-
ical representation of the molecular relationships between
molecules. Molecules are represented as nodes, and the
biological relationship between two nodes is represented
as an edge (line). All edges are supported by at least 1
reference from the literature, from a textbook, or from ca-
nonical information stored in the Ingenuity Pathways
Knowledge Base.
Statistical analysis
SPSS v11.5 (SPSS Inc., Chicago, IL) was used for statis-
tical analysis. For gene expression quantification, we
used the comparative Ct method. First, gene expression
levels for each sample were normalized to the expression
level of the housekeeping gene encoding Glyceralde-
hydes 3-phosphate dehydrogenase (GAPDH) within a
given sample (−⊿Ct); the relative expression of each gene
was calculated with 106 *Log2(−⊿Ct ).The expression of
the pediatric AML samples compared to the control sam-
ples was presented average ± SE. A p<0.05 was considered
statistically significant.
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